PD-L2/B7-DC/PDL2/CD273
產品名稱: PD-L2/B7-DC/PDL2/CD273
英文名稱: PD-L2/B7-DC/PDL2/CD273
產品編號: GMP-TL728
產品價格:
產品產地: 中國
品牌商標: 同立海源生物
更新時間: 2023-08-21T17:05:29
使用范圍: null
| 規格 | 價格 |
| 200μg | 3500.0 |
- 聯系人 : 崔女士
- 地址 : 北京市大興區中關村科技園區大興生物醫藥產業基地華佗路50號院13號樓
- 郵編 : 100085
- 所在區域 : 北京
- 電話 : 186****3653 點擊查看
- 傳真 : 點擊查看
- 郵箱 : cuilimei@seafrom.cn
重組人PD-L2蛋白(Recombinant Human PD-L2 Protein),GMP級
產品貨號:GMP-TL728
產品描述(Description)
Programmed cell death 1 ligand 2 (PD-L2 or PDCD1 ligand 2) is also known as Butyrophilin B7-DC, CD antigen CD273, which belongs to the immunoglobulin superfamily or BTN/MOG family. The expression of PD-L2 is up-regulated by IFNG/IFN-gamma stimulation in monocytes and induced on dendritic cells grown from peripheral blood mononuclear cells with CSF2 and IL-4. PD-L2 Involved in the costimulatory signal, essential for T-cell proliferation and IFNG production in a PDCD1-independent manner. PD-L2 interaction with PDCD1 inhibits T-cell proliferation by blocking cell cycle progression and cytokine production.
分子別名(Synonym)
PDL2、Butyrophilin B7-DC、CD273、PDCD1 ligand 2、PDCD1L2、PDCD1LG2
表達宿主(Expression host)
HEK293細胞
來源(Source)
Human
純度(Purity)
≥95%采用SDS-PAGE凝膠和高效液相色譜分析
內毒素(Endotoxin)
<0.1EU/ug
蛋白序列(Protein Sequence)
DNA序列編碼人PD-L2(NCBI Reference Sequence:NP_079515.2)表達帶有His標簽在C末端
分子量(Molecular Weight)
重組人PD-L2蛋白 包含201個氨基酸,預測理論分子量為24kD
生物活性(Biological Activity)
固定人(His 標簽)10ug/mL( 100 ul/孔)能夠結合人 PD-1(Fc 標簽)的線性范圍是 0.01-1ug/mL
穩定性(Stability)
凍干的樣本的可以在4℃保存24個月,溶解后的液體可以于-20℃保存6-12個月,并且避免反復凍融
組成(Component)
含有6%甘露醇的無菌PBS(PH 7.4)的凍干粉
參考文獻
1、PD-L2 regulates B-1 cell antibody production against phosphorylcholine through an IL-5–dependent mechanism Jerome T. McKay, Marcela A. Haro, Christina A. Daly, Rama D. Yammani, Bing Pang, W. Edward Swords, Karen M. Haas J Immunol. Author manuscript; available in PMC 2018 Sep 15. Published in final edited form as: J Immunol. 2017 Sep 15; 199(6): 2020–2029. Published online 2017 Aug 2. doi: 10.4049/jimmunol.1700555
2、PD-L2 expression in colorectal cancer: Independent prognostic effect and targetability by deglycosylation Huanbin Wang, Han Yao, Chushu Li, Lunxi Liang, Yao Zhang, Hubing Shi, Chongzhi Zhou, Yingxuan Chen, Jing-Yuan Fang, Jie Xu Oncoimmunology. 2017; 6(7): e1327494. Published online 2017 May 16. doi: 10.1080/2162402X.2017.1327494
注意:For research and manufacturing use.
